查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1937850

全球心臟生物标记市场规模、份额、趋势和成长分析报告（2026-2034）

Global Cardiac Biomarkers Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计心臟生物标记市场规模将从 2025 年的 54.4 亿美元成长到 2034 年的 269.7 亿美元，2026 年至 2034 年的复合年增长率为 19.47%。

由于心血管疾病发病率的上升以及对早期诊断和个人化治疗的日益重视，心臟生物标记市场预计将迎来显着增长。随着医疗机构致力于改善患者预后，心臟生物标记在心臟疾病的诊断和管理中的作用日益重要。该市场涵盖多种生物标记物，包括肌钙蛋白、利钠肽和其他蛋白质，这些标记物能够提供有关心臟健康的宝贵资讯。人们对心臟疾病风险因素的认识不断提高，以及对及时干预的迫切需求，正在推动该领域对先进诊断工具的需求。

技术进步在心臟生物标记市场的发展中发挥关键作用，就地检验和实验室诊断技术的创新提高了心臟评估的速度和准确性。高灵敏度检测方法和多重检测平台的开发使医疗服务提供者能够快速获得全面的心臟状况，从而有助于做出明智的决策。此外，远端医疗和远端监测等数位健康技术的整合正在扩大心臟生物标记检测的覆盖范围，尤其是在医疗资源匮乏的地区。随着市场的成熟，那些优先考虑创新并投资研发的公司有望占据更大的市场份额。

此外，心臟生物标记市场深受监管趋势和临床指南的影响，这些趋势和指南都在积极推动生物标记在循环系统诊疗中的应用。随着医疗体系采用实证实践，心臟生物标记正日益融入常规临床工作流程。这种转变推动了对旨在发现新型生物标记并检验其临床效用价值的研究倡议的投资。对个人化医疗的日益重视将进一步推动对能够辅助治疗决策并改善患者预后的心臟生物标记的需求。能够使其产品与临床需求和监管要求相匹配的公司，将在这个充满活力的市场中占据有利地位。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 绘製渗透率和成长前景图
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制
    • 市场机会
    • 市场问题
  • 波特五力分析
  • PESTLE分析

4. 全球心臟生物标记市场（按类型划分）

  • 市场分析、洞察与预测
  • 心肌肌酸激酶（CK-MB）
  • 肌钙蛋白（T 和 I）
  • 肌红蛋白
  • 脑钠肽（BNP）或NT-proBNP
  • 缺血修饰白蛋白（IMA）
  • 其他的

5. 全球心臟生物标记市场（按应用领域划分）

  • 市场分析、洞察与预测
  • 心肌梗塞
  • 郁血性心臟衰竭
  • 急性冠状动脉症候群
  • 动脉粥状硬化
  • 其他的

6. 全球心臟生物标记市场（依检测施行地点划分）

  • 市场分析、洞察与预测
  • 即时检测
  • 检查室检测

7. 全球心臟生物标记市场（按地区划分）

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商格局（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Abbott Laboratories
    • Siemens Healthcare
    • Thermo Fisher Scientific Inc
    • Becton
    • Dickinson And Co
    • Bio-Rad Laboratories
    • Randox Laboratories
    • Alere Inc
    • Beckman Coulter
    • BioMerieux
    • Roche Diagnostics Corporation
简介目录
Product Code: VMR11217049

The Cardiac Biomarkers Market size is expected to reach USD 26.97 Billion in 2034 from USD 5.44 Billion (2025) growing at a CAGR of 19.47% during 2026-2034.

The Cardiac Biomarkers market is poised for significant growth, driven by the increasing prevalence of cardiovascular diseases and the growing emphasis on early diagnosis and personalized treatment approaches. As healthcare providers seek to improve patient outcomes, the role of cardiac biomarkers in diagnosing and managing heart conditions has become increasingly critical. This market encompasses a range of biomarkers, including troponins, natriuretic peptides, and other proteins that provide valuable insights into cardiac health. The rising awareness of heart disease risk factors and the need for timely intervention are propelling the demand for advanced diagnostic tools in this sector.

Technological advancements are playing a pivotal role in the evolution of the Cardiac Biomarkers market, with innovations in point-of-care testing and laboratory diagnostics enhancing the speed and accuracy of cardiac assessments. The development of high-sensitivity assays and multiplex testing platforms is enabling healthcare providers to obtain comprehensive cardiac profiles quickly, facilitating informed decision-making. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, is expanding access to cardiac biomarker testing, particularly in underserved populations. As the market matures, companies that prioritize innovation and invest in research and development will likely capture a larger share of the growing demand.

Furthermore, the Cardiac Biomarkers market is increasingly influenced by regulatory developments and clinical guidelines that promote the use of biomarkers in cardiovascular care. As healthcare systems adopt evidence-based practices, the incorporation of cardiac biomarkers into routine clinical workflows is becoming more prevalent. This shift is driving investment in research initiatives aimed at discovering novel biomarkers and validating their clinical utility. As the focus on personalized medicine continues to grow, the demand for cardiac biomarkers that can guide treatment decisions and improve patient outcomes will expand. Companies that align their product offerings with clinical needs and regulatory requirements will be well-positioned to thrive in this dynamic market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others

By Application

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Point of Care Testing
  • Laboratory Testing

COMPANIES PROFILED

  • Abbott laboratories, Siemens Healthcare, Thermo Fisher Scientific Inc, Becton, Dickinson And Co, BioRad Laboratories, Randox laboratories, Alere Inc, Beckman Coulter, BioMerieux, Roche Diagnostics Corporation

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CARDIAC BIOMARKERS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Myocardial Muscle Creatine Kinase (CK-MB) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Troponins (T and I) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Myoglobin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Brain Natriuretic Peptide (BNPs) or NT-proBNP Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Ischemia Modified Albumin (IMA) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CARDIAC BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Myocardial Infarction Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Congestive Heart Failure Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Acute Coronary Syndrome Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Atherosclerosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CARDIAC BIOMARKERS MARKET: BY LOCATION OF TESTING 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Location Of Testing
  • 6.2. Point of Care Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Laboratory Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CARDIAC BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By Location Of Testing
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By Location Of Testing
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By Location Of Testing
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By Location Of Testing
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By Location Of Testing
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CARDIAC BIOMARKERS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Abbott Laboratories
    • 9.2.2 Siemens Healthcare
    • 9.2.3 Thermo Fisher Scientific Inc
    • 9.2.4 Becton
    • 9.2.5 Dickinson And Co
    • 9.2.6 Bio-Rad Laboratories
    • 9.2.7 Randox Laboratories
    • 9.2.8 Alere Inc
    • 9.2.9 Beckman Coulter
    • 9.2.10 BioMerieux
    • 9.2.11 Roche Diagnostics Corporation